Literature DB >> 22499840

Progressive brain iron accumulation in neuroferritinopathy measured by the thalamic T2* relaxation rate.

A McNeill1, G Gorman, A Khan, R Horvath, A M Blamire, P F Chinnery.   

Abstract

Neuroferritinopathy is an autosomal dominant extrapyramidal movement disorder, caused by FTL gene mutations. Iron decreases the MR T2* decay time, therefore increasing the R2* (R2* = 1 /T2*), which correlates with brain tissue iron content. 3T structural and quantitative MR imaging assessment of R2* in 10 patients with neuroferritinopathy demonstrated a unique pattern of basal ganglia cavitation involving the substantia nigra in older patients and increasing thalamic R2* signal intensity detectable during 6 months. Increasing R2* signal intensity in the thalamus correlated with progression on a clinical rating scale measuring dystonia severity. Thalamic R2* signal intensity is a clinically useful method of objectively tracking disease progression in this form of neurodegeneration with brain iron accumulation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22499840      PMCID: PMC4038493          DOI: 10.3174/ajnr.A3036

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  12 in total

1.  Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease.

Authors:  A R Curtis; C Fey; C M Morris; L A Bindoff; P G Ince; P F Chinnery; A Coulthard; M J Jackson; A P Jackson; D P McHale; D Hay; W A Barker; A F Markham; D Bates; A Curtis; J Burn
Journal:  Nat Genet       Date:  2001-08       Impact factor: 38.330

2.  Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects.

Authors:  Domenico Aquino; Alberto Bizzi; Marina Grisoli; Barbara Garavaglia; Maria Grazia Bruzzone; Nardo Nardocci; Mario Savoiardo; Luisa Chiapparini
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

3.  Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from alzheimer's disease patients.

Authors:  Michael J House; Timothy G St Pierre; Kris V Kowdley; Thomas Montine; James Connor; John Beard; Jose Berger; Narendra Siddaiah; Eric Shankland; Lee-Way Jin
Journal:  Magn Reson Med       Date:  2007-01       Impact factor: 4.668

4.  Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation.

Authors:  Patrick F Chinnery; Douglas E Crompton; Daniel Birchall; Margaret J Jackson; Alan Coulthard; Anne Lombès; Niall Quinn; Adrian Wills; Nicholas Fletcher; John P Mottershead; Paul Cooper; Mark Kellett; David Bates; John Burn
Journal:  Brain       Date:  2006-12-02       Impact factor: 13.501

5.  Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights.

Authors:  Michelangelo Mancuso; Guido Davidzon; Roger M Kurlan; Rabi Tawil; Eduardo Bonilla; Salvatore Di Mauro; James M Powers
Journal:  J Neuropathol Exp Neurol       Date:  2005-04       Impact factor: 3.685

6.  Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla.

Authors:  R J Ordidge; J M Gorell; J C Deniau; R A Knight; J A Helpern
Journal:  Magn Reson Med       Date:  1994-09       Impact factor: 4.668

7.  T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation.

Authors:  A McNeill; D Birchall; S J Hayflick; A Gregory; J F Schenk; E A Zimmerman; H Shang; H Miyajima; P F Chinnery
Journal:  Neurology       Date:  2008-04-29       Impact factor: 9.910

8.  Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene.

Authors:  R Vidal; B Ghetti; M Takao; C Brefel-Courbon; E Uro-Coste; B S Glazier; V Siani; M D Benson; P Calvas; L Miravalle; O Rascol; M B Delisle
Journal:  J Neuropathol Exp Neurol       Date:  2004-04       Impact factor: 3.685

Review 9.  Susceptibility-weighted imaging: technical aspects and clinical applications, part 2.

Authors:  S Mittal; Z Wu; J Neelavalli; E M Haacke
Journal:  AJNR Am J Neuroradiol       Date:  2009-01-08       Impact factor: 3.825

10.  Magnetic field correlation as a measure of iron-generated magnetic field inhomogeneities in the brain.

Authors:  Jens H Jensen; Kamila Szulc; Caixia Hu; Anita Ramani; Hanzhang Lu; Liang Xuan; Maria F Falangola; Ramesh Chandra; Edmond A Knopp; John Schenck; Earl A Zimmerman; Joseph A Helpern
Journal:  Magn Reson Med       Date:  2009-02       Impact factor: 4.668

View more
  6 in total

Review 1.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

Review 2.  Cerebral Iron Deposition in Neurodegeneration.

Authors:  Petr Dusek; Tim Hofer; Jan Alexander; Per M Roos; Jan O Aaseth
Journal:  Biomolecules       Date:  2022-05-17

Review 3.  The presence and role of iron in mild traumatic brain injury: an imaging perspective.

Authors:  Eric J Nisenbaum; Dmitry S Novikov; Yvonne W Lui
Journal:  J Neurotrauma       Date:  2014-01-09       Impact factor: 5.269

4.  Voxel-based analysis in neuroferritinopathy expands the phenotype and determines radiological correlates of disease severity.

Authors:  M J Keogh; B S Aribisala; J He; E Tulip; D Butteriss; C Morris; G Gorman; R Horvath; P F Chinnery; Andrew M Blamire
Journal:  J Neurol       Date:  2015-07-04       Impact factor: 4.849

5.  The neuropsychiatry of hyperkinetic movement disorders: insights from neuroimaging into the neural circuit bases of dysfunction.

Authors:  Bradleigh D Hayhow; Islam Hassan; Jeffrey C L Looi; Francesco Gaillard; Dennis Velakoulis; Mark Walterfang
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-08-26

Review 6.  Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management.

Authors:  Niraj Kumar; Philippe Rizek; Mandar Jog
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-03-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.